Clinical Trial Detail

NCT ID NCT01522820
Title Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Roswell Park Cancer Institute
Indications

Advanced Solid Tumor

Therapies

Rasdegafusp alfa

Sirolimus

Age Groups: adult senior

No variant requirements are available.